Actively Recruiting
Phase 1 Study of a DNA Vaccine pTVG-HP and Nivolumab with Targeted Treatment of Resistant Tumors in Men with Recurrent Oligometastatic Prostate Cancer
Led by University of Wisconsin, Madison · Updated on 2026-03-11
14
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying whether combining an experimental DNA vaccine called pTVG-HP with the drug nivolumab can boost the immune systems ability to fight metastatic tumors in men with non-castrate, recurrent, oligometastatic prostate cancer. This pilot phase 1 trial explores if this combination, along with targeted ablation of resistant lesions, can eliminate tumor sites. Participants will receive injections of the pTVG-HP vaccine into the arm and two doses of nivolumab, a monoclonal antibody, as part of the treatment. Alongside these medicines, targeted radiation therapy will be used to destroy resistant cancer lesions. This combined approach aims to attack the cancer through multiple methods. During the study, participants will undergo regular monitoring including prostate-specific antigen PSA testing over several years to assess response and progression. Researchers will track any side effects, toxicity, and survival outcomes. Blood samples will be collected for immune studies up to one year after treatment, and participants will be followed for up to five years to measure long-term effects and cancer control.
CONDITIONS
Brief Title
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Research Team
C
Cancer Connect
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here